A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
Ancestry (3)
- African - African parental proportion (phv00347731.v1.p1)
- Caucasian - Caucasian parental proportion (phv00347732.v1.p1)
- Native - Native (Zapotecas) parental proportion (phv00347733.v1.p1)
Anthropometry (2)
- Height - Height measured at enrollment (phv00347715.v1.p1)
- Weight - Weight at the moment of giving informed consent (phv00347716.v1.p1)
Demographics (2)
- Age_recruitment - Subject age at the moment of giving informed consent (phv00347714.v1.p1)
- Sex - Gender of participant (phv00347713.v1.p1)
Disease Events (5)
- CHF - If the patient has congestive heart failure (phv00347726.v1.p1)
- Diabetes - If the patient has diabetes (either type I or II) (phv00347725.v1.p1)
- DVT - If warfarin was indicated to manage deep vein thrombosis (phv00347719.v1.p1)
- PE - If warfarin was indicated to manage pulmonary embolism (phv00347720.v1.p1)
- Valve - If warfarin was indicated to manage mechanical heart valve replacement (phv00347722.v1.p1)
Medications (3)
- Aspirin - If the patient uses aspirin (phv00347727.v1.p1)
- Azoles - If the patient uses medications containing azoles (phv00347729.v1.p1)
- Statins - If the patient uses statins (phv00347728.v1.p1)
Substance Use (1)
- Smoking - If the patient smokes (phv00347730.v1.p1)
Other (29)
- AF - If warfarin was indicated to manage atrial fibrillation (phv00347721.v1.p1)
- Affection_Status - Case control status of the subject for Warfarin Sensitivity. Controls are subjects with warfarin requirements of 4-6mg/day. Cases are subjects with warfarin stable dose <4mg/day or >6mg/day (phv00347706.v1.p1)
- Analyte_Type - Analyte Type (phv00347737.v1.p1)
- Body_Site - Body site where sample was collected (phv00347736.v1.p1)
- Consent - Consent group as determined by DAC (phv00347703.v1.p1)
- Genotyping_Center - Name of the center which conducted genotyping (phv00347743.v1.p1)
- Genotyping_Technology - Genotyping technology used to analyze the samples (phv00347741.v1.p1)
- Histological_Type - Cell or tissue type or subtype of sample (phv00347739.v1.p1)
- Is_Tumor - Tumor status (phv00347738.v1.p1)
- Other - If the patient has other conditions such as: hypertension, hypercholesterolemia, asthma, benign prostate hyperplasia, depression, glaucoma, osteoporosis, etc. (phv00347724.v1.p1)
- Sample_ID - De-identified Sample ID (phv00347735.v1.p1)
- Sample_ID - Sample ID (phv00347708.v1.p1)
- Sample_Source - Source repository where samples originate (phv00347709.v1.p1)
- SAMPLE_USE - Sample Use (phv00347711.v1.p1)
- Sequencing_Center - Name of the center which conducted sequencing (phv00347744.v1.p1)
- Sequencing_Technology - Sequencing technology used to analyze the samples (phv00347742.v1.p1)
- Source_Sample_ID - Sample ID used in the Source Repository (phv00347710.v1.p1)
- Source_Subject_ID - Subject ID used in the Source Repository (phv00347705.v1.p1)
- Stroke - If warfarin was indicated to manage stroke (phv00347723.v1.p1)
- Subject_ID - De-identified Subject ID (phv00347712.v1.p1)
- Subject_ID - Subject ID (phv00347734.v1.p1)
- Subject_ID - Subject ID (phv00347702.v1.p1)
- Subject_ID - Subject ID (phv00347707.v1.p1)
- Subject_Source - Source repository where subjects originate (phv00347704.v1.p1)
- Type_Analysis - Genotyping or Sequencing (phv00347740.v1.p1)
- Warf_Daily_Dose - Maintenance warfarin daily dose (under stable INR) (phv00347717.v1.p1)
- Warf_Resistant - If the patient is resistant to warfarin (phv00352973.v1.p1)
- Warf_Sensitive - If the patient is sensitive to warfarin (phv00352972.v1.p1)
- Warf_Week_Dose - Maintenance warfarin weekly dose (under stable INR) (phv00347718.v1.p1)